Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.1158/2326-6066.CIR-18-0847
![](/digitum/image/email_logo.png)
![](/digitum/image/logo-facebook.png)
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Guillamón, Concepción F. | - |
dc.contributor.author | Martínez Sánchez, María V. | - |
dc.contributor.author | Gimeno, Lourdes | - |
dc.contributor.author | Campillo, José A. | - |
dc.contributor.author | Server Pastor, Gerardo | - |
dc.contributor.author | Martínez García, Jerónimo | - |
dc.contributor.author | Martínez Escribano, Jorge | - |
dc.contributor.author | Torroba, Amparo | - |
dc.contributor.author | Ferri, Belén | - |
dc.contributor.author | Abellán, Daniel J. | - |
dc.contributor.author | Legaz Pérez, Isabel | - |
dc.contributor.author | López Álvarez, María R. | - |
dc.contributor.author | Moya Quiles, María R. | - |
dc.contributor.author | Muro, Manuel | - |
dc.contributor.author | Minguela, Alfredo | - |
dc.contributor.other | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Ciencias Sociosanitarias | - |
dc.date.accessioned | 2024-07-11T11:31:59Z | - |
dc.date.available | 2024-07-11T11:31:59Z | - |
dc.date.issued | 2019-08-01 | - |
dc.identifier.citation | Cancer Immunology Research, 2019, Vol. 7 (8), pp. 1307–1317 | es |
dc.identifier.issn | Print: 2326-6066 | - |
dc.identifier.issn | Electronic: 2326-6074 | - |
dc.identifier.uri | http://hdl.handle.net/10201/142997 | - |
dc.description | © 2019 American Association for Cancer Research. This document is the Published version of a Published Work that appeared in final form in Cancer Immunology Research. To access the final edited and published work see https://doi.org/10.1158/2326-6066.CIR-18-0847 | - |
dc.description.abstract | Therapies using NK cells (NKc) expanded/activated ex vivo or stimulated in vivo with new immunostimulatory agents offer alternative opportunities for patients with recurrent/refractory tumors, but relevant biomarkers to guide the selection of patients are required for optimum results. Overall survival of 249 solid cancer patients was evaluated in relation to the genetics and/or the expression on peripheral blood NKcs of inhibitory and activating killer-cell immunoglobulin-like receptors (iKIR and aKIR, respectively), HLA class I ligands, CD226 (also known as DNAM-1), and NKG2A. Compared with patients with higher expression, patients with low expression of CD226 on total NKcs showed shorter mean overall survival (60.7 vs. 98.0 months, P < 0.001), which was further reduced in presence of telomeric aKIRs (KIR2DS1-DS5 and/or KIR3DS1, 31.6 vs. 96.8 months, P < 0.001). KIR2DL2/S2+, KIR3DL1+, KIR2DL1+, and KIR2DL3+ NKc subsets in the presence of their cognate ligands primarily contributed to shortening patients’ overall survival by increasing the sensitivity to CD226 downmodulation in aKIR-rich telomeric genotypes. In patients with high tumor burden who died during the follow-up period, aKIR-rich telomeric genotypes were associated with: (i) specific downmodulation of CD226 on educated NKcs but not on CD8+ T cells or uneducated NKcs, (ii) lower expression of CD226 and higher expression of NKG2A on aKIR+ NKcs, and (iii) lower numbers of total CD56dim NKcs. The reduced expression of CD226 on NKcs with aKIR-rich genotypes may be a biomarker indicative of NKc hyporesponsiveness in patients that could benefit from new NKc immune-stimulatory therapies. | es |
dc.format | application/pdf | es |
dc.format.extent | 11 | es |
dc.language | eng | es |
dc.publisher | American Association for Cancer Research | - |
dc.relation | This work was funded by MINECO - Instituto de Salud Carlos III (PI1302297) and Fundación Séneca, Agencia de Ciencia y Tecnología, Región de Murcia (20812/PI/18). C.F. Guillamón was funded by the Fundación para el estudio y el desarrollo de la inmunogenética en Murcia (FEYDIM). M.V. Martínez-Sánchez was funded by the Asociación Pablo Ugarte (APU). | es |
dc.rights | info:eu-repo/semantics/embargoedAccess | es |
dc.title | Activating KIRs on Educated NK Cells Support Downregulation of CD226 and Inefficient Tumor Immunosurveillance | es |
dc.type | info:eu-repo/semantics/article | es |
dc.relation.publisherversion | https://aacrjournals.org/cancerimmunolres/article/7/8/1307/469581/Activating-KIRs-on-Educated-NK-Cells-Support | - |
dc.embargo.terms | Si | - |
dc.identifier.doi | https://doi.org/10.1158/2326-6066.CIR-18-0847 | - |
Aparece en las colecciones: | Artículos: Ciencias Sociosanitarias |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
1307.pdf | 1,6 MB | Adobe PDF | ![]() Visualizar/Abrir Solicitar una copia |
Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.